Program Description
Metabolic dysfunction–associated steatohepatitis (MASH) is a progressive, inflammatory liver disease that represents the most severe form of metabolic dysfunction–associated steatotic liver disease (MASLD). Driven by the accumulation of fat in the liver and other metabolic disturbances, MASH can advance to fibrosis, cirrhosis, hepatocellular carcinoma, and end-stage liver failure. Because MASH is often asymptomatic until advanced stages, early testing and accurate identification of at-risk individuals are crucial to prevent progression and improve long-term outcomes. This program will equip pharmacists and managed care professionals with up-to-date knowledge on MASH pathophysiology, clinical presentation, and disease burden, alongside emerging data from pivotal clinical trials of approved and investigational therapies. Participants will explore recent guideline updates and evidence-based, personalized treatment approaches tailored to disease severity, comorbidities, and patient-specific factors. The program will also address the rapidly evolving therapeutic landscape, the importance of early identification and intervention, and managed care strategies to optimize access, outcomes, and health care resource utilization.
Target audience: Specialty Pharmacists, Managed Care
Pharmacists
Type of activity: Application
Release date: June 16, 2026
Expiration date: July 16, 2026
Time to complete activity: 1.0 hour
Learner level: Foundational, Intermediate
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Explain the metabolic drivers of metabolic dysfunction-associated steatohepatitis (MASH), along with its key clinical manifestations, common comorbid conditions, diagnostic evaluation, and overall impact on disease burden.
- Interpret current data and guideline recommendations underpinning FDA-approved therapies for MASH as well as the mechanisms of action of late-stage investigational agents.
- Apply managed care strategies that facilitate timely diagnosis and equitable access to evidence-based MASH treatments, with the goal of improving clinical outcomes and mitigating downstream health care costs.